Characteristics Of Our Hypoxemic COVID-19 Pneumonia Patients Receiving Corticosteroids And Mortality-Associated Factors
Tarih
2022Yazar
Sengul, Aysun
Mutlu, Pinar
Ozdemir, Ozer
Satici, Celal
Turan, Muzaffer Onur
Arslan, Sertac
Ogang, Nalan
Unsal, Zuhal Ekici
Bozkus, Fulsen
Capraz, Aylin
Demirkol, Mustafa Asim
Mutlu, Levent Cern
Gulhanm, Pinar Yildiz
Alkilinc, Ersin
Fazlioglu, Nevin
Soyler, Yasemin
Kabalak, Pinar Akin
Kizilgoz, Derya
Turan, Pakize Ayse
Yildirim, Fatma
Aydemir, Yusuf
Sen, Nazan
Mirici, Arzu
Üst veri
Tüm öğe kaydını gösterÖzet
Background COVID-19 is a disease associated with diffuse lung injury that has no proven effective treatment yet. It is thought that glucocorticoids may reduce inflammation-mediated lung injury, disease progression, and mortality. We aimed to evaluate our patient's characteristics and treatment outcomes who received corticosteroids for COVID-19 pneumonia. Methods We conducted a multicenter retrospective study and reviewed 517 patients admitted due to COVID-19 pneumonia who were hypoxemic and administered steroids regarding demographic, laboratory, and radiological characteristics, treatment response, and mortality-associated factors. Results Of our 517 patients with COVID-19 pneumonia who were hypoxemic and received corticosteroids, the mortality rate was 24.4% (n = 126). The evaluation of mortality-associated factors revealed that age, comorbidities, a CURB-65 score of >= 2, higher SOFA scores, presence of MAS, high doses of steroids, type of steroids, COVID-19 treatment, stay in the intensive care unit, high levels of d-dimer, CRP, ferritin, and troponin, and renal dysfunction were associated with mortality. Conclusion Due to high starting and average steroid doses are more associated with mortality, high-dose steroid administration should be avoided. We believe that knowing the factors associated with mortality in these cases is essential for close follow-up. The use of CURB-65 and SOFA scores can predict prognosis in COVID-19 pneumonia.